A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Public ClinicalTrials.gov record NCT04227847. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have seven groups or "parts." * Part A will find out how much SEA-CD70 should be given to participants * Part B will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with MDS. * Part C will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with AML. * Part D will find out how much SEA-CD70 with azacitidine should be given to participants * Part E will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is compared to azacitidine alone and if it works to treat participants with MDS or MDS/AML that has not been treated. * Part F will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat participants with MDS or MDS/AML. * Part G will find out how much SEA-CD70 with azacitidine and with venetoclax should be given to participants with AML. Also, to evaluate safety and tolerability of PF-08046040 in combination with azacitidine and venetoclax in participants with previously untreated AML who are unfit for standard induction chemotherapy.
Study identification
- NCT ID
- NCT04227847
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 170 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 7, 2020 (Actual)
- Primary completion
- Jul 4, 2027 (Estimated)
- Completion
- Jul 3, 2028 (Estimated)
- Last update posted
- Sep 9, 2026
2020 – 2028
United States locations
- U.S. sites
- 47
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| Dept. of Medicine, UAB ONeal Comprehensive Cancer Center | Birmingham | Alabama | 35294 | — |
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | — |
| IP Address: City of Hope Investigational Drug Services(IDS) | Duarte | California | 91010 | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| UCLA Hematology-Oncology Clinic | Los Angeles | California | 90095 | — |
| Colorado Blood Cancer Institute, Lab | Denver | Colorado | 80218 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Presbyterian/St. Luke's Medical Center | Denver | Colorado | 80218 | — |
| The University of Kansas Cancer Center ,Investigational Drug Services | Fairway | Kansas | 66205 | — |
| The University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | — |
| The University of Kansas Hospital | Kansas City | Kansas | 66160 | — |
| University of Kansas Hospital Cambridge North Tower A | Kansas City | Kansas | 66160 | — |
| University of Kansas Medical center Medical office building | Kansas City | Kansas | 66160 | — |
| University of Kansas Medical Center Research Institute | Kansas City | Kansas | 66160 | — |
| The University of Kansas Cancer Center - Overland Park | Overland Park | Kansas | 66210 | — |
| The University of Kansas Cancer Center - Indian Creek Campus | Overland Park | Kansas | 66211 | — |
| The University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Norton Hospitals, Inc | Louisville | Kentucky | 40202 | — |
| Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD | Louisville | Kentucky | 40207 | — |
| Norton Cancer Institute, St. Matthews Campus | Louisville | Kentucky | 40207 | — |
| Norton Women & Children's Hospital | Louisville | Kentucky | 40207 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber/Mass General Brigham Cancer Care, Inc | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Karmanos Cancer Institute Weisberg Cancer Treatment Center | Farmington Hills | Michigan | 48334 | — |
| The University of Kansas Cancer Center - Medical Oncology Clinic | Kansas City | Missouri | 64116 | — |
| The University of Kansas Cancer Center -North | Kansas City | Missouri | 64154 | — |
| The University of Kansas Cancer Center - Lee's Summit | Lee's Summit | Missouri | 64064 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| CUIMC Research Pharmacy | New York | New York | 10032 | — |
| The New York and Presbyterian Hospital | New York | New York | 10032 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| The Ohio State University Wexner Medical Center/James Cancer Hospital | Columbus | Ohio | 43210 | — |
| Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Medical University of South Carolina- Ashley River Tower | Charleston | South Carolina | 29425 | — |
| Medical University of South Carolina- Investigational Drug Services | Charleston | South Carolina | 29425 | — |
| Medical University of South Carolina- University Hospital | Charleston | South Carolina | 29425 | — |
| Baylor Research Institute | Dallas | Texas | 75204 | — |
| Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy | Dallas | Texas | 75246 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| Swedish Medical Center | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04227847, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2026 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04227847 live on ClinicalTrials.gov.